Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Carotid Atherosclerosis : Innovative Imaging Biomarkers. Study Case-control

NCT02748941 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2017-01-12
Last updated
2026-04-03

Condition(s) studied

Carotid Stenosis

Investigational drug(s) / intervention(s)

HITS quantification, Ultrasound examinations, High Resolution MRI

HITS quantification, Ultrasound examinations, High Resolution MRI: Simultaneously measure the occurrence of the event (ischemic stroke) and the characteristics of the atheromatous plaque Description of different modalities: HITS quantification Ultrasound examinations: * Ulceration \>2 mm * Plaque thickness * GSM: computer analysis after normalization of most informative longitudinal view (image with maximum plaque area) using Photoshop * CEUS: plaque vascularization detection after bolus injection of SONOVUE on a video recording from the injection of the contrast (Vuebox - Bracco imaging) High Resolution MRI: * Stenosis severity, intraplaque hemorrhage, large lipid-rich necrotic core, ulceration or cap rupture and Brain MRI will be evaluated * Quantification of shear stresses (Pa) on the surface of the plaque mi-RNA identification and quantification

Study summary

Cerebrovascular accident (CVA) constitutes a major health public problem. This represents the second cardiovascular death cause. CVA is ischemic in 80% of cases. Atheroma of large arteries, mainly carotid, is involved in about 20% of cases.

After several high grade studies (NASCET, ECST, ACAS, ACST), carotid surgery is based on stenosis calculation by Doppler ultrasound, CT angiography, MRI angiography or arteriography.

The composition of the plaque, showing its vulnerability, is associated with embolic risk and stroke. The therapeutic strategy based only on the narrowing of the arterial lumen is not satisfactory enough to prevent the occurrence of a transient ischemic attack (TIA) or an ipsilateral stroke due to carotid stenosis. Thus, new techniques emerge, to evaluate in vivo the inflammation of the plaque, its embolic consequences or the mechanical stress it undergoes. These techniques are: High Resolution MRI (HR MRI), evaluation of the Gray Scale Median (GSM) level, study of the plaque vascularization with Contrast Enhanced ultrasound (CEUS), High Intensity Transient Signals (HITS) by transcranial Doppler, micro RNA profile (mi RNA). These different modalities must be combined in order to increase the efficiency.

Based on these encouraging results, the investigator aim at evaluating the ability of different methods or their combination to predict the occurrence of ischemic stroke or TIA due to emboli from a carotid atherosclerotic plaque. Before considering a cohort study, he investigator want to evaluate the performance of each of these new methods in the characterization of carotid plaque instability. Performance evaluation will allow us to choose secondarily the most relevant association.

The investigator propose, as a first step, to make a case-control study with these methods, the cases are patients who had an ischemic stroke (authenticated by both the clinical exam and brain MRI) on the same side as the carotid stenosis and the controls are patients with carotid stenosis but without ischemic stroke. This study is a cross-sectional study because it simultaneously measures the occurrence of the event (ischemic stroke) and the characteristics of the atheromatous plaque.

Over a 2 year period, 45 symptomatic patients and 105 asymptomatic patients will be included with a carotid stenosis with at least a 50% caliber constriction according to NASCET criteria. (North American Symptomatic Carotid Endarterectomy Trial).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Carotid stenosis ≥ 50% NASCET * Case: ipsilateral carotid stenosis stroke, certified by MRI or CT in the preceding month, with no others causes of stroke * Control: no clinical sign or MRI hint for a recent stroke * Signed informed consent form * Patient affiliated to a social security system or equivalent Exclusion Criteria: * Modified Rankin scale \> 3 * Homolateral stroke or TIA \> 1 month * Medical history of homolateral carotid surgery, cervical radiation, carotid occlusive, homolateral intracranial stenosis, risk of developing arterial thromboembolic events * Renal failure (creatinine clearance \< 50 ml/min) * Contraindication to ultrasound (sonovue) * Contraindication to MRI and its contrast media (Gadolinium) * Inability to sign informed consent * Inability to undergo any of the technics (claustrophobia…) * Serious co-morbid disease, dementia * Neurological disease with no carotid disease * Risk of pregnancy or pregnancy or breastfeeding * Adult under reinforced guardianship or legal guardian * Patient not understanding French

Primary outcome measure(s)

  • Number of HITS per hour in doppler ultrasonography — Day 1
  • Ulceration > 2 mm presence in doppler ultrasonography — Day 1
  • GSM (Gray Scale Median) quantification in doppler ultrasonography — Day 1
  • CEUS (Contrast Enhanced UltraSound ) — Day 1
    signal intensity amplification quantification and Ulceration \> 2 mm
  • hemorrhage intra-plaque présence in HR MRI — Day 1
  • large lipid-rich necrotic core présence in HR MRI — Day 1
  • ulceration or cap rupture présence in HR MRI — Day 1

Trial sites (1)

FacilityCityRegionStatus
Hospices Civils de Lyon - Service de radiologie Bron France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02748941 on ClinicalTrials.gov ↗ ← All trials in France